Drug news
FDA approves Lucentis (Genentech) for treatment of Diabetic Macular Edema
The FDA on 10 August 2012 approved Lucentis (ranibizumab injection) from Genentech for the treatment of Diabetic Macular Edema (DME), a sight-threatening eye disease that occurs in people with diabetes. An injection of the drug is administered once a month by a health care professional. Lucentis is intended to be used along with good diabetic blood sugar control.
DME is a condition in which fluid leaks into the macula, the center part of the retina where sharp, straight-forward vision occurs. The fluid makes the macula swell, causing vision to blur.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins